Continuing allergy immunotherapy after an assessment in Turkey may be possible, but it is not automatic. The answer depends on the prescribed preparation, route of treatment, patient factors and a clinician who agrees to provide continuing care in the country of residence. The appropriate plan should be established before treatment begins, rather than left for the patient to organise after returning home.
Discuss suitability and continuing care before booking: Contact Istanbul Allergy on WhatsApp or call +90 850 433 93 93.
Two different questions need clarification: continuing treatment in your home country and administering treatment at home. Injection immunotherapy ordinarily requires an appropriately equipped clinical service. Selected sublingual treatments can be taken at home under a prescribed programme after appropriate initiation and training. These arrangements are not interchangeable, and receiving one supervised dose does not authorise independent use of another treatment.
Istanbul Allergy can be contacted to discuss assessment with Prof. Dr. Ahmet Akçay and the coordination a proposed programme would require. Share the patient’s age, country of residence and existing reports. This article explains the questions to resolve; it does not guarantee that a particular product can be supplied abroad, imported or accepted by another clinician.
Start With Suitability, Not the Travel Itinerary
Allergen immunotherapy is considered for selected clinically relevant allergies. A positive skin or blood test alone does not establish that treatment should begin. The clinician considers the symptom pattern, relevant exposure, current management and safety factors. A programme that is practical for travel still needs a sound clinical indication; convenience cannot substitute for assessing whether it is appropriate for the individual.
Explain how symptoms affect sleep, school, work and daily activities. Bring earlier results and describe the response to existing treatments. This helps the clinician decide whether immunotherapy merits discussion or whether another approach would be more useful first. Do not assume that a larger test panel or a request for an injection creates eligibility for a specific programme.
For international patients, clinical suitability and continuing-care feasibility should be assessed together. If the proposed treatment cannot be maintained after departure, starting during a short visit may not be sensible. Ask which decisions can be made from existing records and which require examination. The initial consultation may produce a clear plan without making immediate treatment initiation the default outcome.
Know Whether the Programme Is SCIT or SLIT
Subcutaneous immunotherapy, often abbreviated SCIT, involves allergen injections. Sublingual immunotherapy, or SLIT, delivers a prescribed allergen preparation under the tongue. Their supervision, administration and product requirements differ. Tablets, drops and injections should not be treated as interchangeable versions of the same universally available medicine. The specific preparation and its instructions matter.
If treatment is proposed, ask for its name, manufacturer, formulation, relevant allergen and intended route. Understand whether the course is continuous, seasonal or otherwise scheduled for that product and indication. A general phrase such as allergy vaccine is not enough information to organise care across borders. The receiving clinician needs to know what is actually being prescribed.
This article primarily concerns respiratory allergen immunotherapy. Venom immunotherapy and food oral immunotherapy have distinct indications and practical requirements. A plan for one should not be copied into another. If your concern involves insect stings or food allergy, identify that explicitly when enquiring so the appropriate specialist pathway can be discussed rather than inferred from a general immunotherapy page.
Injection Immunotherapy Needs a Receiving Clinical Service
Patients continuing injection immunotherapy in another country need a clinician or service willing and able to manage the proposed treatment. This includes reviewing the records, assessing suitability and providing appropriate administration and observation. Do not assume that any clinic offering injections will accept an externally prescribed allergen preparation. Their policies and clinical responsibilities may differ.
Routine self-injection at home should not be presented as the solution to inconvenient travel. Allergen injections can cause systemic reactions and ordinarily require a properly prepared clinical environment. A relative with healthcare experience or a nearby pharmacy does not automatically replace the responsible service. This guide does not provide instructions for home administration or an injection schedule.
Contact the potential receiving service before starting treatment abroad. Ask whether it accepts the particular preparation, what documentation it needs and whether a new consultation is required. Obtain a clear answer about responsibility rather than relying on an informal assurance that someone will probably give the injections. If acceptance is uncertain, resolve it before building the treatment plan around that assumption.
Why Observation Matters After Allergy Injections
Allergy injections require observation because reactions can occur after administration. Patients are commonly asked to remain under observation for at least thirty minutes, with the actual instructions determined by the service and circumstances. Do not shorten the required period to catch a flight, attend a meeting or fit another appointment. The waiting period is part of the treatment arrangement.
The clinic also needs to assess relevant changes before a dose, such as worsening asthma or a previous reaction. A patient who has tolerated earlier injections still needs the agreed precautions. If symptoms develop while waiting, tell the staff immediately. A quiet previous course does not mean that future administration can be moved to an unprepared setting without clinical review.
When comparing continuing-care options, ask about emergency preparation and the process for reporting reactions. A service that can administer a medicine but cannot manage an unexpected systemic reaction may not provide the appropriate setting. International coordination should preserve the necessary assessment and supervision, rather than treat the appointment as a purely technical task that anyone can perform.
Sublingual Treatment May Continue at Home Under a Specific Plan
Selected sublingual immunotherapy preparations are used at home after appropriate initiation in accordance with the product and clinical plan. For many tablet programmes, the first dose is given under medical supervision. This does not remove the need for education about reactions, missed doses and circumstances in which the patient should contact the treating team. Home use remains prescribed treatment, not an independent experiment.
Ask what training and written instructions are provided before departure. Understand the expected routine, relevant precautions and which symptoms need prompt advice. Product-specific instructions can differ, so do not rely on a leaflet for another tablet or drops supplied elsewhere. An emergency plan, including prescribed adrenaline where indicated, should reflect the actual programme and patient.
Before returning home, confirm who will review progress and provide continuing prescriptions or supply. Home administration may reduce the need for repeated clinic dosing, but it does not make the programme independent of clinical care. If the medicine cannot be obtained appropriately where you live, the practical question remains unresolved even when the administration method appears convenient.
Products and Doses Cannot Be Swapped Informally
Two preparations containing a similarly named allergen are not automatically equivalent. Concentrations, units, formulation and supporting instructions can differ. A clinician receiving the patient may need to review the proposed product carefully or recommend a different approach. Do not substitute an injection vial, tablet or drops independently because the label mentions the same pollen or dust mite.
This is particularly important when a product is unavailable after returning home. The solution is not to search for a similar-looking alternative and continue the previous amount. Any transition requires appropriate prescribing and clinical judgement. A written plan should explain who makes that decision and what the patient should do while the question is being resolved.
Ask about future supply before beginning the course. A programme that can be started during a visit still needs a realistic route for later treatment. International guidance or another country’s approval does not establish the local authorisation, availability or age indication of every preparation. Confirm the relevant arrangements for the patient’s country rather than assuming that an international brand name settles them.
Establish the Handover Before the First Treatment
A useful handover identifies the clinician initiating treatment, the service providing ongoing care and the responsibilities of each. It should be clear who prescribes, who administers where applicable, who assesses progress and who changes the plan after a problem. An exchange of documents without agreement about responsibility can leave important decisions unassigned.
Ask the receiving clinician to review the proposed arrangement in advance. They may require their own consultation, additional information or a different preparation. That is a clinical and service decision, not something a foreign booking can override. A patient should not be left carrying a product between clinics in the hope that someone will eventually accept it.
Keep the plan understandable to everyone involved, including the patient or caregiver. Confirm the start of continuing care and what happens if an appointment is delayed. The purpose is a reliable pathway after return, rather than a one-time transfer of paperwork. If the arrangement changes, obtain updated instructions before proceeding under assumptions that no longer apply.
The Records a Receiving Clinician May Need
Documentation should describe the diagnosis, relevant allergy findings and reason for immunotherapy. The receiving service also needs details of the actual preparation and prescribed regimen, including the stage reached. For injection treatment, administration records and information about previous reactions can be important. Ask the initiating team which documents will be supplied and the receiving clinician what they require.
Records should make dates and units clear. An informal message saying the patient is on maintenance is not a complete treatment record. The last administration and any interruption need to be identifiable by the responsible clinician. This article does not provide a generic dose table because interpretation and adjustment must reflect the actual preparation, history and service protocol.
If documents need translation, clarify the format before departure. Preserve the original information as well as any translation and check that the receiving team can understand it. A concise clinical summary can complement detailed records, but should not replace essential product and administration information. Good documentation supports clinical decisions; it cannot compel a service to accept a programme it has not agreed to manage.
Medicine Supply, Import and Prescription Arrangements
Supplying a product in one country does not establish that it can be taken into, prescribed or replenished in another. Ask the relevant authorities, pharmacy or responsible service about the actual product and route. Requirements depend on the destination and circumstances. Do not infer permission from a travel blog, another patient’s experience or the fact that the medicine has a prescription label.
Separate personal transport from continuing supply. A quantity taken on one journey may not solve the need for later treatment. Ask how future prescriptions, renewals and dispensing will be arranged. If delivery is proposed, confirm the lawful and practical process with the responsible provider rather than assuming that international shipping is a routine part of the service.
Avoid purchasing an extended supply before suitability and storage have been clarified. Ask what happens if the clinical plan changes or the receiving clinician recommends another preparation. This guide does not establish a particular country’s import rules, a refund policy or product availability. The practical goal is a confirmed supply pathway that matches the agreed treatment, not simply possession of several packages.
Storage and Transport Must Follow the Actual Product
Storage requirements depend on the preparation. Some products require controlled refrigeration, while others have different instructions. Obtain written guidance for the actual medicine from the responsible service or pharmacist. Do not assume that every immunotherapy product belongs in the same kind of cool bag or that a hotel refrigerator automatically provides the required conditions.
Plan the full journey, including transfers, airport time and the route from arrival to the receiving service. Ask how temperature control, packaging and documentation will be handled where relevant. Avoid improvising with direct ice contact or other methods that could damage the product. The correct transport arrangement should be confirmed for that medicine rather than borrowed from advice about another treatment.
If storage has been outside the specified conditions or the packaging appears compromised, contact the responsible professional before using it. Appearance alone cannot confirm suitability. A transport problem may require a decision about replacement or review, which should not be made independently to avoid missing a dose. Keep product identification and the supplied instructions available throughout the journey.
Missed Doses and Interruptions Require Individual Advice
Travel, illness or appointment changes can interrupt treatment. The appropriate response depends on the route, preparation, stage of treatment and length of the gap, among other factors. Do not double a dose, shorten intervals or restart a previous amount independently to catch up. Obtain instructions from the team responsible for the programme.
Injection immunotherapy may require clinician-directed adjustment after an interruption. Sublingual programmes also have product-specific advice about missed treatment and restarting. A schedule found online may not apply to the patient’s preparation. Ask for clear written guidance before travel, including how to contact the team and what information to provide if a dose is missed.
If a planned receiving appointment is cancelled, tell the responsible clinician promptly rather than waiting until the gap becomes longer. The aim is to resolve the interruption safely, not to preserve a calendar at any cost. Repeated difficulty attending or obtaining treatment should trigger review of the programme’s feasibility and the practical support needed to continue it.
Asthma and Changes in Health Affect Continuing Treatment
Asthma control is an important safety consideration in allergen immunotherapy. Report worsening breathing symptoms, increased need for reliever medicine or recent urgent treatment to the responsible clinician. Do not conceal a change because a dose or journey has already been arranged. The programme may need reassessment before administration, and clinical suitability takes priority over the travel timetable.
Also report new diagnoses, changes in medicines, pregnancy or a significant reaction during the course. These circumstances require individual review; a previous plan should not be assumed to apply unchanged forever. Do not stop important medicines independently to preserve an immunotherapy schedule. The treating team should consider the full clinical picture and explain any necessary adjustment.
Before transferring care, make sure the receiving clinician knows about relevant changes, not just the original diagnosis. For adults or complex conditions, another specialist may need to be involved. Continuing care should include the patient’s current health and symptom control rather than focus only on the last recorded dose. A complete handover is a clinical review, not merely a delivery arrangement.
Recognising Reactions and Knowing Whom to Contact
Ask which local or mild symptoms may be expected with the prescribed treatment and which require prompt review. A reaction should be described accurately, including its timing and any treatment received. Do not independently reduce, increase or repeat a dose based on another patient’s experience. The responsible clinician should explain how a reported reaction affects the next step.
Severe breathing difficulty, throat or tongue swelling, faintness or collapse can indicate anaphylaxis and require immediate emergency action. Follow the individual plan and use prescribed adrenaline promptly when indicated. Call the local emergency number; in Turkey it is 112. Antihistamines do not replace adrenaline for anaphylaxis, and routine clinic messaging is not an emergency response service.
Before departure, identify the appropriate emergency route at home as well as the contact for non-emergency treatment questions. A clinic in another country may not be available when symptoms occur. Written instructions should make these different responsibilities clear. After an emergency, follow the treating medical team’s advice and arrange review before continuing the programme under an outdated plan.
Children and Caregivers Need a Shared Routine
For a child, treatment planning must fit age, product indications and the family’s ability to follow the programme. Parents or caregivers should understand administration arrangements, symptoms to report and the review schedule. A regimen used by an adult or another child should not be copied. Product choice and practical supervision need an individual assessment.
Discuss school days, travel between households and who will take responsibility if the usual caregiver is unavailable. If treatment is prescribed for home use, the instructions should be understandable to the actual person supporting it. An adolescent should participate in planning, including how to communicate missed treatment or a reaction without embarrassment. Reliable information is more useful than an unrealistic expectation of perfect adherence.
Keep relevant records and contact details accessible as care moves between countries. If the family cannot maintain the proposed appointments or supply, raise that early. The solution may involve revising the plan rather than trying to manage around missing supervision. Treatment should support the child’s daily life and health, with clear responsibility for decisions as circumstances change.
Follow-Up Should Measure Benefit as Well as Adherence
Continuing treatment involves more than documenting doses. Review should consider symptoms, sleep, activity, medicine needs and the impact on daily life. The appropriate measures depend on the condition and exposure pattern. A symptom diary may help, but repeated testing without a clear clinical question is not automatically the best way to judge whether the programme is helping.
Agree when progress will be assessed and which clinician will make decisions about continuation or change. Expectations should be realistic: benefit can take time, and not every patient responds in the same way. Do not interpret an early quiet period as proof that treatment is complete or that all other medicines can be stopped independently.
For an international patient, ensure that reviews are scheduled rather than left indefinitely open. Some discussions may be suitable online, while examination or testing may require local attendance. If several clinicians are involved, ask who integrates the information. A clear follow-up structure helps identify ineffective or impractical treatment early and avoids continuing a course simply because no one has taken responsibility for reassessment.
Costs and Repeat Travel Should Be Discussed Separately
The starting consultation, product, administration visits and continuing review can involve different charges. Ask each relevant service to describe what it provides and what is billed separately. A fee paid in Turkey should not be assumed to cover appointments in another country. Likewise, a receiving clinic’s willingness to assess the patient does not establish its future charges.
If return visits to Istanbul are proposed, ask why they are needed and which decisions they support. Some care may be feasible locally, but that must be agreed. Do not book repeated flights simply because the programme is long-term, and do not assume travel will never be necessary because home administration has been mentioned. The schedule follows the actual treatment and coordination plan.
Request current information rather than relying on an average package price. Product access, clinical circumstances and the receiving service can change the practical budget. The purpose is to understand the ongoing commitment before starting. A sustainable plan needs clarity about responsibility and supply as well as the initial clinical decision, so cost discussions should happen alongside those arrangements.
What an Online Consultation Can Help Clarify
An online consultation may help review existing reports, identify the proposed treatment and organise questions for the receiving clinician. It can be useful before travel or for appropriate follow-up. Share readable records and explain whether treatment has already begun. A review of an existing programme raises different questions from a request to start a new one.
Remote review cannot administer an injection, replace required observation or certify an unverified product’s storage history. It also cannot create local prescribing authority or require another service to accept care. Those arrangements must be resolved with the relevant professionals and authorities. Severe or rapidly changing symptoms need local medical assessment rather than waiting for a scheduled international video appointment.
A useful outcome may be a list of specific next steps rather than immediate approval to continue. Ask what records, examination or coordination remain necessary and who will arrange them. The aim is to reduce uncertainty before the patient travels or takes another dose. Online convenience should support a workable clinical pathway rather than conceal gaps in supervision or supply.
A Checklist Before You Leave Turkey
Before departure, confirm the exact treatment, the stage reached and the written instructions for continuing it. Identify the receiving clinician or service and verify that acceptance has been agreed. Make sure the necessary clinical, product and administration records are available. Understand the next appointment, prescription and review arrangements rather than relying on a general promise to follow up later.
Check supply and transport arrangements for the actual preparation, including storage and any destination requirements that apply. Review the plan for missed doses, new illness and reactions. Keep emergency treatment accessible where prescribed and know the emergency route in the country of residence. If any essential part is unresolved, discuss it with the responsible team before assuming the programme can proceed unchanged after travel.
For patients considering immunotherapy assessment at Istanbul Allergy, share the country of residence and continuing-care questions at the first enquiry. The appropriate goal is a clinically suitable programme with clear responsibility on both sides of the journey. Returning home can be compatible with treatment when the necessary arrangements are established; it should not mean leaving the patient to improvise the next step.
Discuss the Whole Care Pathway Before Starting
Read the allergen immunotherapy treatment guide and Plan Your Visit information, then share your country of residence and continuing-care questions with Istanbul Allergy. Confirm the suitable assessment and the arrangements needed before treatment begins.
Discuss suitability and continuing care before booking: Contact Istanbul Allergy on WhatsApp or call +90 850 433 93 93.
Frequently Asked Questions
Can I continue immunotherapy in my country after an assessment in Turkey?
It may be possible if the treatment is suitable and supply, prescribing and clinical responsibility are arranged. A receiving clinician must agree to the actual programme; continuation should not be assumed before starting.
Does continuing at home mean I can inject myself?
No. Injection immunotherapy ordinarily requires an appropriately equipped clinical service and observation. Continuing in your home country is different from self-administration at your residence.
Can sublingual immunotherapy be taken at home?
Selected preparations can be used at home under their prescribed programme after appropriate initiation and training. Product-specific instructions, follow-up and a suitable reaction plan remain necessary.
Can another clinic refuse to accept the treatment?
Yes. A receiving service needs to assess the preparation, records and its own responsibilities. A prescription or booking in another country does not require it to accept the programme.
What records should be transferred?
Ask the receiving service for its requirements. These may include the diagnosis, relevant results, product and regimen details, administration history, dates and previous reactions. Clear records support assessment but do not replace agreement about responsibility.
Can I swap to another product with the same allergen name?
Not independently. Formulations, units and instructions can differ. Any substitution or transition requires appropriate clinical review and prescribing.
How do I transport the medicine?
Follow the actual product’s storage and transport instructions and confirm destination requirements through the relevant service or authority. Do not assume every preparation uses the same temperature or packaging.
What should I do after missing treatment?
Contact the responsible team for instructions that match the preparation, route, stage and interruption. Do not double a dose, shorten intervals or restart a previous amount independently.
Can treatment continue if my asthma worsens?
Report worsening symptoms promptly and obtain the responsible clinician’s advice before proceeding. Asthma control is an important safety consideration, and a pre-booked appointment does not override clinical suitability.
Can I finish immunotherapy during one short visit?
No. Established programmes generally need continuing treatment and follow-up over years. Clarify the purpose of the initial visit and how the rest of the course will be managed.
Does food oral immunotherapy follow the same plan?
No. Food oral immunotherapy is a separate specialist pathway with its own indications, supervision and ongoing requirements. A respiratory immunotherapy schedule should not be copied into it.
Can online follow-up replace a local treating service?
It can support appropriate review and coordination but cannot administer injections, provide required observation or create local prescribing and emergency arrangements. Responsibilities should be clear before departure.
Sources and Further Reading
These sources explain general clinical principles and examples of care arrangements. They do not establish Istanbul Allergy product availability, another clinician’s acceptance, or the prescribing and import requirements of every country. Confirm those for the actual treatment and destination.
- ASCIA: Allergen immunotherapy — patient information updated May 2026.
- ACAAI: Sublingual immunotherapy tablets.
- University of Utah Health: Transferring immunotherapy care — example of one service’s requirements, not a worldwide transfer policy.
- AAAAI: Immunotherapy administration documentation.
- AAAAI: Sublingual immunotherapy safety and action-plan resources.
- AAAAI: Supervision and waiting location for allergy injections.
- CDC Yellow Book 2026: Severely allergic travellers — treatment and travel coordination.
- AAO-HNS: Clinical practice guideline on immunotherapy for inhalant allergy (2024).
- Cambridge University Hospitals: Injection immunotherapy information.
- University Hospitals Sussex: Dust mite injection immunotherapy — product-specific patient leaflet.
- ACAAI: Allergen immunotherapy — general information.
- AAAAI: Sublingual tablet product information — US indications do not establish Turkish or destination-country access.
- NHS: Anaphylaxis — recognition and emergency response.
